Protara Therapeutics Inc. (TARA) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, TARA scores 43 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6 / 20 (ROIC -34.7%; FCF yield 0%), Whale 13F Flow at 9 / 20 (institutional accumulation and options positioning), Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Fundamental Cash Engine, which indicate that the cash-generation profile and insider-side signals are the primary drags on the score. For a prospective investor, the upside case rests on the balance sheet and macro pillars holding steady while the company advances, but the verdict reflects that the current fundamentals do not yet offset the negative cash flow and weak insider and flow signals. Valuation tradeoffs are difficult to assess from the available data because earnings-based multiples are not available in source data.

Protara Therapeutics Inc. (TARA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M across all listed periods, so the source data does not identify a current income-generating business line.

Per the SEC financials, reported operating and net losses widened from FY 2023 to FY 2025, and free cash flow remained negative in each period shown. Gross, operating, and net margins are each recorded as 0%, and ROIC is -34.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. Cash declined from $162.8M in FY 2024 to $49.7M in FY 2025, a reduction that aligns with the negative free cash flow reported in FY 2025.

The news wire contains six items, all tagged with a YELLOW light and labeled MARKET WIRE. Items include a Simply Wall St stock analysis, an Investing.com report stating that Cantor Fitzgerald reiterated its rating, a Yahoo! Finance Canada seasonal returns chart, a TradingView note on the Q3'26 earnings revenue estimate of 0 USD, a Yahoo Finance Australia seasonal returns chart, and a GlobeNewswire release stating that Protara Therapeutics completed enrollment of its Phase 2b study. The Phase 2b enrollment completion is the only item describing a company-specific development, while the remaining items are market commentary or data summaries. Risk watch items include the zero-revenue estimate for the upcoming quarter and the continued negative cash flow. The Butterfly Supply-Chain Graph reports no supply chain, no butterfly links, and no proprietary signals.

• What is the product pipeline and expected timing of the Phase 2b readout, and what is the cash runway given the FY 2025 cash balance of $49.7M and FCF of $-56.5M?
• What is the company's total debt, since the debt field is reported as N/A for every period?
• Why is EPS reported as N/A across all periods, and what share count underlies the $148.9M market capitalization?
• What caused the decline in cash from $162.8M to $49.7M between FY 2024 and FY 2025, and are any financing transactions expected?
• What institutional or insider ownership changes underlie the Whale 13F and Insider Conviction pillar scores, given that the holders dataset is empty?